On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

In a perfect universe, the persuasiveness of an argument would not be based mostly on who said it. In the world we live in, ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Eli Lilly ( LLY -1.63%) and Microsoft ( MSFT 1.20%) are two high-flying dividend stocks in the S&P 500 index. Here's why the ...

RISES OVER 1.6% AT IT’S HIGH FOR THE DAY AFTER EARLY DROP AND THE POWER INFLOW SIGNAL ...

BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

ODBM is one of 91 organizations that received grants through a competitive round of Lilly Endowment’s Nurturing Children ...

The drug developed by U.S. pharmaceutical giant Eli Lilly and Co. will be offered to patients experiencing dementia and mild ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

GLP-1 agonists – of which Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) are the most ...